Selank is a synthetic heptapeptide derived from tuftsin, an immune-modulating fragment of immunoglobulin G. Developed at the Russian Academy of Sciences, it produces anxiolytic effects comparable to benzodiazepines while simultaneously reducing IL-6, TNF-alpha, and IL-1beta. For autoimmune patients, this dual action targets a well-documented problem: psychological stress triggers flares by elevating pro-inflammatory cytokines through glucocorticoid receptor resistance. Selank is approved in Russia for generalized anxiety disorder. It is not FDA-approved in the US but was returned to Category 1 compounding status in February 2026.
What Is Selank?
Selank is a seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Its parent molecule is tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of immunoglobulin G. Tuftsin was discovered in the 1970s as an immune stimulator that activates macrophages, neutrophils, and natural killer cells. It circulates in blood as part of the IgG molecule and is released through enzymatic cleavage in the spleen.
The Institute of Molecular Genetics at the Russian Academy of Sciences added a Pro-Gly-Pro tripeptide extension to tuftsin's C-terminus. This extension serves a specific pharmacological purpose: it dramatically improves metabolic stability by resisting enzymatic degradation that would otherwise break down the native tuftsin sequence within minutes.
The result is a peptide that preserves tuftsin's immunomodulatory properties while adding entirely new neurological activity. Selank crosses the blood-brain barrier and modulates GABAergic neurotransmission. Russia approved it in 2009 under the brand name Selanc as an intranasal spray for generalized anxiety disorder and neurasthenia.
From Immune Peptide to Anxiolytic
The trajectory from immune modulator to anxiety treatment is unusual. Most anxiolytics were designed as such from the start. Selank was not. Its developers were studying tuftsin derivatives for immune modulation when they discovered unexpected effects on animal behavior: reduced anxiety, improved stress tolerance, and enhanced exploratory activity in rodent models.
This dual identity is precisely what makes selank relevant for autoimmune disease. The stress-immune connection is not a metaphor. It is a measurable, bidirectional pathway with specific molecular mediators. Selank acts on both sides.
The Stress-Autoimmune Axis: Why This Matters
Stress triggers autoimmune flares. This is not speculation. Stojanovich (2010) reviewed the epidemiological data and found that up to 80% of autoimmune patients report uncommon emotional stress before disease onset. The mechanism is specific, reproducible, and involves defined molecular pathways.
How Stress Drives Inflammation
Acute stress activates the hypothalamic-pituitary-adrenal (HPA) axis. Cortisol rises. In the short term, cortisol suppresses immune function. This is why brief stressors rarely cause problems.
Chronic stress changes the equation. Prolonged cortisol exposure causes glucocorticoid receptor resistance in immune cells. The receptors downregulate, meaning immune cells stop responding to cortisol's anti-inflammatory signal. The result is paradoxical: high cortisol levels with simultaneously elevated pro-inflammatory cytokines. IL-6 rises. TNF-alpha rises. The body loses its built-in brake on inflammation.
This has direct consequences for autoimmune disease. Chronic stress shifts the T-helper cell balance toward Th1 and Th17 dominance, the very immune profiles that drive tissue destruction in Hashimoto's, rheumatoid arthritis, lupus, and psoriasis. Regulatory T cells (Tregs), which normally prevent autoimmune attack, decline in number and function.
The Problem with Standard Anxiolytics
Benzodiazepines reduce anxiety effectively. They do nothing for immune dysregulation. SSRIs take weeks to work and carry their own side-effect profiles. Neither drug class addresses the inflammatory cascade that connects psychological stress to autoimmune tissue damage.
This is the gap selank occupies. It reduces anxiety through GABA modulation while simultaneously acting on the cytokine pathways that translate stress into flares. No conventional anxiolytic does both.
How Selank Works
Anxiolytic Mechanism: GABA Modulation [Grade B]
Selank enhances GABAergic neurotransmission in the frontal cortex. Kasian et al. (2016, PMC4757669) mapped its effects using gene expression analysis and found that selank modulates the expression of 84 genes related to the GABAergic system. This includes GABA-A receptor subunit genes, GABA transporters, and enzymes involved in GABA synthesis and metabolism.
The scale of this gene-expression shift is notable. Benzodiazepines act on a single binding site on the GABA-A receptor. Selank appears to reshape the entire GABAergic tone of the cortex. The clinical effect resembles benzodiazepine anxiolysis, but without the sedation, dependence, tolerance, or withdrawal that limit benzodiazepine use.
Selank also modulates serotonergic and dopaminergic neurotransmission. This broader neurochemical profile likely explains the "antiasthenic" and "psychostimulant" effects reported in Russian clinical trials, where patients on selank showed improved energy and motivation alongside reduced anxiety. Benzodiazepines produce the opposite: sedation and cognitive slowing.
Immune Modulation: Cytokine Regulation [Grade C+]
The immune effects of selank are less thoroughly studied than the anxiolytic effects but are mechanistically consistent with its tuftsin heritage.
Uchakina et al. (2020, PMID 32621722) examined selank's effects on cytokine profiles under social stress conditions. Selank reduced IL-1beta, IL-6, TNF-alpha, and TGF-beta1. These are not random inflammatory markers. IL-6 is the primary driver of the acute-phase response and is elevated in virtually every autoimmune condition. TNF-alpha drives tissue destruction in RA, psoriasis, and IBD. IL-1beta is central to inflammasome-mediated damage.
Earlier work by the same group (Uchakina 2008, PMID 18577961) demonstrated immunomodulatory changes in patients with anxiety-asthenic disorders, suggesting that selank's immune effects are not purely theoretical constructs from animal models but translate to human physiology.
The tuftsin connection matters here. Tuftsin itself is a known immunomodulator that activates phagocytic cells and enhances host defense. Selank preserves this immunomodulatory core while adding the Pro-Gly-Pro stability extension. The immune effects are not incidental. They are baked into the molecule's ancestry.
T-Helper Cell Rebalancing
Autoimmune diseases involve a shift in T-helper cell balance. In Hashimoto's, the dominant pattern is Th1/Th17 overactivation. In lupus, it is a mix of Th1, Th17, and aberrant B-cell activation. In psoriasis, the IL-23/IL-17 axis drives keratinocyte hyperproliferation.
Selank's cytokine-modulating profile suggests a shift away from this pro-inflammatory dominance. Reducing IL-6 directly curtails Th17 differentiation, since IL-6 combined with TGF-beta is the primary signal driving naive T cells toward the Th17 lineage. Reducing TNF-alpha dampens the Th1 arm. Together, these shifts move the immune system toward a more regulated state.
This is immunomodulation, not immunosuppression. Selank does not broadly suppress immune function the way methotrexate or prednisone does. It recalibrates. This distinction is important for autoimmune patients who need their immune system to function against infections while reducing the self-directed attack.
Neuroprotective Effects
Beyond anxiety and immunity, selank demonstrates neuroprotective properties that may benefit the cognitive symptoms common in autoimmune disease. It mildly upregulates brain-derived neurotrophic factor (BDNF) and modulates the enkephalin system.
This is relevant because Hashimoto's brain fog, lupus cognitive dysfunction, and Sjogren's-associated fatigue all involve neuroinflammatory components. By reducing neuroinflammation through cytokine modulation while supporting neuroplasticity through BDNF, selank addresses cognitive complaints from two directions.
However, for primary cognitive enhancement, semax is the stronger option. Selank's neuroprotective effects are secondary to its anxiolytic and immune-modulating roles.
How to Read the Evidence Grades
Multiple RCTs or meta-analyses
Highest confidence in efficacy
Single RCT or strong mechanistic + clinical evidence
Promising with important caveats
Preliminary, mechanistic, or small pilot data
Early-stage or theoretical
Evidence Base
Anxiety: Grade B (Russian RCTs)
Seredenin et al. (2008, PMID 18454096) conducted the most important selank study: a randomized controlled trial in 62 patients diagnosed with generalized anxiety disorder and neurasthenia. Patients received either selank nasal spray or medazepam, a standard benzodiazepine.
Selank matched medazepam's anxiolytic potency. Anxiety scores declined comparably in both groups. But selank produced two additional effects that medazepam did not: antiasthenic activity (reduced fatigue, improved stamina) and mild psychostimulant effects (increased motivation and mental clarity). There was no sedation, no cognitive impairment, no dependence, and no withdrawal syndrome upon discontinuation.
This study earns a Grade B rather than Grade A for two reasons. First, it is a single RCT. Second, Russian clinical trial methodology has historically differed from Western standards in reporting and regulatory oversight. No independent Western replication exists. That said, the study was properly randomized, controlled, and published in a peer-reviewed journal.
Key finding
Selank matched benzodiazepine anxiolytic potency in a 62-patient RCT while adding antiasthenic and psychostimulant effects. No sedation, no dependence, no withdrawal (Seredenin 2008, PMID 18454096).
Russia approved selank in 2009 based on this and supporting preclinical data. It has been prescribed for over 15 years under the brand name Selanc. Post-marketing surveillance has not revealed significant safety signals, though the quality of Russian pharmacovigilance data is difficult to verify independently.
Immune Modulation: Grade C+ (Preclinical + Small Human Data)
The evidence for selank's immune effects sits below the anxiety data in strength but is mechanistically coherent.
Uchakina et al. (2020, PMID 32621722) used a social stress model to evaluate selank's effects on inflammatory cytokines. Under stress conditions that normally elevate IL-1beta, IL-6, TNF-alpha, and TGF-beta1, selank treatment significantly reduced all four markers. This study demonstrates that selank's immune effects are not merely an artifact of reduced anxiety. The peptide directly modulates cytokine production.
The earlier Uchakina et al. (2008, PMID 18577961) study examined patients with anxiety-asthenic disorders and found immunomodulatory changes during selank treatment. This is valuable because it confirms that the cytokine modulation observed in preclinical models translates to human physiology. The sample sizes were small, but the direction of effect was consistent.
Seredenin and Kozlovskaya (2012) published a comprehensive review of selank's pharmacology covering both the anxiolytic and immune pathways, arguing that the two are mechanistically linked through the stress-cytokine cascade. Their framing aligns with the broader psychoneuroimmunology literature on stress-driven immune dysregulation.
Autoimmune Applications: Grade C (Theoretical)
This requires honesty. No study has tested selank in any autoimmune population. Not Hashimoto's. Not lupus. Not RA. Not psoriasis. Not IBD.
The rationale for autoimmune applications is an extrapolation from three established facts: (1) stress triggers autoimmune flares through cytokine elevation, (2) selank reduces anxiety, and (3) selank reduces the specific cytokines elevated by stress. The logic chain is sound. The direct evidence does not exist.
This matters because extrapolation across diseases has failed many times in medicine. Interventions that reduce IL-6 in one context do not automatically help in another. The autoimmune immune environment is complex, involving tissue-specific antigens, germinal center dynamics, and epitope spreading that generic cytokine reduction may not address.
Grade C is the honest assessment. Promising mechanism. No clinical proof in autoimmune patients.
Selank vs Semax
Selank and semax are companion peptides, both developed at the same Russian institution, both approved in Russia, and both returned to FDA Category 1 status in February 2026. They are often discussed together because practitioners frequently combine them.
Origin
Primary Effect
Mechanism
Best For
Evidence Level
Dosing Route
FDA Status
Monthly Cost
Selank and Semax are complementary peptides often used together. Both are approved in Russia; neither is FDA-approved.
The key distinction: selank is primarily an anxiolytic with immune-modulating properties. Semax is primarily a cognitive enhancer with neuroprotective properties. They act through different parent molecules (tuftsin vs ACTH fragment) and different receptor systems (GABA vs BDNF).
For autoimmune patients, the choice depends on the dominant symptom. Stress-driven flares and anxiety point toward selank. Brain fog and cognitive fatigue point toward semax. Some practitioners prescribe both, typically selank in the morning and semax in the afternoon, or vice versa depending on whether the patient needs calming or activating effects earlier in the day.
Read the full comparison in our peptides for autoimmune disease guide.
Dosage and Administration
Intranasal Spray (Primary Route)
The Russian prescribing protocol for Selanc nasal spray provides the most established dosing framework:
- Dose: 200-400 mcg per nostril, 2-3 times daily
- Total daily dose: 800-2,400 mcg (0.8-2.4 mg)
- Cycling: 2-4 weeks on, 1-2 weeks off
- Onset: Anxiolytic effects within 5-15 minutes
- Immune effects: Gradual, developing over days to weeks of consistent use
Intranasal delivery bypasses first-pass liver metabolism and provides rapid absorption through the nasal mucosa's rich vascular supply. This explains the fast onset of anxiolytic effects and is the primary reason intranasal is preferred over other routes.
Subcutaneous Injection
Some practitioners use subcutaneous injection at 250-500 mcg daily. This route provides more consistent bioavailability but is less convenient and unnecessary for most users given intranasal effectiveness. Injection is typically reserved for patients who do not tolerate nasal administration.
N-Acetyl Selank Amidate (NASA)
N-acetyl selank amidate is a modified form with enhanced metabolic stability and bioavailability. The N-acetyl group protects the peptide's N-terminus from aminopeptidase degradation, while the C-terminal amide resists carboxypeptidases. Dosing is similar to standard selank.
Some users report stronger or longer-lasting effects with the amidate form, though no head-to-head comparison study exists. Both forms are available through compounding pharmacies and research peptide suppliers.
Important Caveats on Dosing
All dosing information comes from Russian prescribing protocols and practitioner experience, not from FDA-approved labeling. There is no FDA-approved dose. Compounding pharmacies may formulate at varying concentrations. Quality and purity vary between suppliers.
Important
No FDA-approved dosing exists for selank. All dosing guidelines derive from Russian clinical practice and practitioner protocols. Work with a knowledgeable physician. Do not self-prescribe based on internet forums.
Safety, Legal Status, and Access
Side Effects
Russian post-marketing data spanning 15+ years of Selanc prescriptions reports a favorable safety profile. The most common side effect is mild nasal irritation from the spray formulation. Systemic adverse effects are rare in the published literature.
Crucially, selank does not produce the side effects that limit benzodiazepine use: no sedation, no cognitive impairment, no physical dependence, no tolerance development, and no withdrawal syndrome. The Seredenin RCT specifically evaluated these parameters and found none.
However, the absence of reported side effects is partly a function of limited research. Selank has been studied in far fewer patients than any standard anxiolytic. Rare adverse effects that occur in 1 per 1,000 or 1 per 10,000 patients would not be detected in the existing data.
Legal Status
Selank occupies a specific regulatory position:
- Russia: Approved since 2009 as Selanc nasal spray for GAD and neurasthenia. Available by prescription.
- United States: Not FDA-approved. Returned to FDA Category 1 in February 2026, meaning it can be legally compounded by 503A and 503B pharmacies with a valid prescription from a licensed physician.
- Other countries: Regulatory status varies. Not approved in the EU, UK, Canada, or Australia for any indication.
Category 1 status is significant. It means selank is recognized as having adequate safety data for compounding and has not been placed on the FDA's "difficult to compound" or "demonstrable clinical need" restriction lists. This is the same status held by other peptides like BPC-157 and thymosin alpha 1 following the February 2026 reclassification.
Drug Interactions
No formal drug interaction studies have been conducted with selank. This is a genuine limitation. For autoimmune patients, the most relevant unknowns are:
- Immunosuppressants (methotrexate, azathioprine, mycophenolate): Unknown interaction. Selank's immune-modulating effects could theoretically potentiate or counteract immunosuppression.
- Biologics (adalimumab, infliximab, rituximab): Unstudied. The combination of cytokine modulation from selank plus targeted immune blockade from biologics has no safety data.
- Benzodiazepines: Both act on GABAergic pathways. Additive sedation is theoretically possible, though selank itself does not produce sedation.
- SSRIs/SNRIs: Selank modulates serotonin. Combining with serotonergic drugs has unknown risk.
- Thyroid medications (levothyroxine): No known interaction, but timing separation is prudent.
The standard advice applies with particular force here: discuss any peptide use with your prescribing physician, especially if you take immunosuppressants, biologics, or psychiatric medications.
Access
Selank is available through two channels in the US:
- Compounding pharmacies (503A/503B): Requires a prescription. Quality is regulated. This is the recommended route.
- Research peptide suppliers: Labeled "for research use only." Quality varies widely. Look for certificates of analysis (COA) showing 98%+ purity from third-party HPLC testing.
Selank is not available as a dietary supplement. It is a synthetic peptide that does not occur naturally in food and cannot be legally marketed as a supplement under DSHEA.
Condition-Specific Relevance for Autoimmune Patients
While no direct clinical evidence exists for selank in autoimmune disease, the stress-cytokine connection is particularly relevant for certain conditions.
Hashimoto's Thyroiditis
Hashimoto's patients frequently report that stress triggers symptom flares: increased fatigue, weight fluctuation, brain fog, and mood disturbance. The mechanism involves stress-driven IL-6 and TNF-alpha elevation that accelerates thyroid tissue destruction and TPO antibody production. Selank's profile of anxiety reduction plus IL-6/TNF-alpha modulation addresses this cascade at two points. Read more about Hashimoto's natural treatment approaches.
Lupus (SLE)
Lupus flares correlate strongly with psychological stress. Disease activity scores (SLEDAI) increase following stressful life events. The IL-6 pathway is central to lupus pathogenesis, driving both the inflammatory and the serological features of the disease. See our guide on lupus natural remedies for the full supplement evidence.
Rheumatoid Arthritis
TNF-alpha is the primary therapeutic target in RA, as demonstrated by the clinical success of anti-TNF biologics (adalimumab, infliximab, etanercept). Stress elevates TNF-alpha through glucocorticoid receptor resistance. Selank's ability to reduce TNF-alpha under stress conditions is mechanistically aligned with RA pathophysiology.
Sjogren's Syndrome
Sjogren's involves lymphocytic infiltration of salivary and lacrimal glands, with significant fatigue and cognitive complaints that overlap with anxiety symptoms. The stress-immune connection in Sjogren's is underresearched but clinically observed by rheumatologists.
Psoriasis
Psychological stress is one of the most commonly cited triggers for psoriatic flares. The IL-17/IL-23 axis that drives psoriasis is influenced by upstream IL-6 signaling, which selank modulates. Stress reduction alone improves psoriasis outcomes in clinical trials of mindfulness-based stress reduction (MBSR).
Where Selank Fits in an Autoimmune Protocol
Selank is not a first-line intervention. It belongs in the advanced tier of an autoimmune protocol, after foundational elements are in place.
Tier 1 (Foundation): Start Here
Before considering selank, establish the basics: autoimmune diet (AIP, Mediterranean, or condition-specific), vitamin D optimization, omega-3 fatty acids, magnesium, and gut healing. These have stronger evidence and broader applicability. See our best supplements for autoimmune disease guide.
Tier 2 (Condition-Specific)
Address your specific condition's known deficiencies and targeted interventions. Selenium for Hashimoto's. NAC for lupus. Curcumin for RA.
Tier 3 (Advanced): Where Selank Lives
Selank fits alongside LDN, BPC-157, and other peptides for autoimmune disease in the advanced tier. These interventions have promising mechanisms but limited direct evidence in autoimmune populations. They are reasonable options for patients who have optimized foundation and condition-specific layers and still experience stress-triggered flares.
The best candidate for selank is an autoimmune patient with documented stress-triggered flares, significant anxiety that worsens disease activity, and inadequate response to conventional stress management. This is a specific phenotype, not a universal recommendation.
Take the AutoimmuneFinder quiz to build your personalized protocol and determine which tier of interventions matches your current situation.
Frequently Asked Questions
Can selank help reduce autoimmune flares caused by stress?
Selank reduces IL-6, TNF-alpha, and IL-1beta under stress conditions (Uchakina 2020), and it has demonstrated anxiolytic effects comparable to benzodiazepines in a 62-patient RCT (Seredenin 2008). This dual action on both stress and inflammatory cytokines is theoretically relevant to stress-triggered autoimmune flares. However, no clinical trial has tested selank specifically in autoimmune patients. The rationale is strong but the direct evidence does not exist yet.
How does selank compare to semax for brain fog?
Semax is the better-studied option for cognitive enhancement and brain fog. It upregulates BDNF and nerve growth factor, with Russian clinical data supporting its use in cognitive impairment. Selank's primary strength is anxiolysis and immune modulation, not cognition. Some practitioners stack both peptides for patients who have anxiety plus brain fog.
Is selank FDA-approved or legal in the US?
Selank is not FDA-approved for any indication. It is approved in Russia as Selanc nasal spray for generalized anxiety disorder and neurasthenia. In February 2026, selank was returned to FDA Category 1 status, meaning it can be legally compounded by 503A/503B pharmacies with a valid prescription. It is not a dietary supplement.
What is the recommended selank nasal spray dosage?
The Russian prescribing protocol uses 200-400 mcg per nostril, 2-3 times daily, in cycles of 2-4 weeks on and 1-2 weeks off. Anxiolytic effects typically appear within 5-15 minutes of intranasal administration. These doses come from Russian clinical practice and the Seredenin RCT, not from FDA-approved labeling.
Does selank actually reduce IL-6 and other inflammatory cytokines?
Uchakina et al. (2020, PMID 32621722) demonstrated that selank reduces IL-1beta, IL-6, TNF-alpha, and TGF-beta1 under social stress conditions. Earlier work by the same group (2008, PMID 18577961) showed immunomodulatory shifts in patients with anxiety-asthenic disorders. These findings are consistent but come from a small number of studies, mostly from Russian research groups.
Can I use selank alongside immunosuppressant medications?
No clinical study has examined selank in combination with methotrexate, biologics, or other immunosuppressants. The interaction profile is unknown. Because selank modulates immune function, theoretical interactions exist. Discuss any peptide use with your prescribing rheumatologist, endocrinologist, or neurologist before starting.
How long does selank take to work for anxiety?
Anxiolytic effects from intranasal selank appear within 5-15 minutes in most users, comparable in speed to sublingual benzodiazepines. The immune-modulating effects develop over days to weeks of consistent use. The Russian prescribing protocol recommends 14-day treatment courses for generalized anxiety disorder.
Evidence Summary
| Intervention | Application | Evidence Grade | Key Study | PMID |
|---|---|---|---|---|
| Selank (anxiety) | Generalized anxiety disorder, neurasthenia | Grade B | Seredenin et al. 2008, 62-patient RCT vs medazepam | 18454096 |
| Selank (GABA genes) | Anxiolytic mechanism | Grade B | Kasian et al. 2016, 84 GABAergic genes modulated | PMC4757669 |
| Selank (cytokines) | IL-6, TNF-alpha, IL-1beta reduction under stress | Grade C+ | Uchakina et al. 2020, social stress model | 32621722 |
| Selank (immune) | Immunomodulation in anxiety patients | Grade C+ | Uchakina et al. 2008 | 18577961 |
| Selank (autoimmune) | Hashimoto's, lupus, RA, psoriasis | Grade C | No direct studies; theoretical extrapolation | N/A |
| Stress-autoimmune axis | Stress as trigger for flares | Established | Stojanovich 2010 (review) | Review |
This article is for educational purposes only and does not constitute medical advice. Selank is not FDA-approved and has not been evaluated for the treatment of any autoimmune condition. If you are experiencing anxiety or depression, consult a healthcare provider. Do not discontinue prescribed medications or begin peptide therapy without discussing with your treating physician. The evidence for selank in autoimmune disease is theoretical (Grade C); the anxiety evidence (Grade B) comes primarily from Russian clinical trials without independent Western replication. Always work with a qualified healthcare provider before making changes to your treatment plan.